**
Patients using weight-loss injections, specifically GLP-1 medications, are advised to be vigilant following updated guidance from the Medicines and Healthcare products Regulatory Agency (MHRA). The agency has highlighted a small but significant risk of developing severe acute pancreatitis associated with these treatments, which are increasingly prescribed for obesity management.
Growing Use of GLP-1 Medications
Recent data indicates that approximately 1.6 million adults across England, Wales, and Scotland utilised GLP-1 medications, such as semaglutide (marketed as Wegovy and Ozempic) and tirzepatide (Mounjaro), for weight loss between early 2024 and early 2025. These drugs have gained popularity due to their effectiveness in aiding weight reduction, but the MHRA’s latest findings have prompted a reassessment of their safety profile.
The patient information leaflets for these medications already noted that pancreatitis could occur in about one in 100 individuals, categorising it as an “uncommon” side effect. However, the rise in reported cases has necessitated a more cautious approach.
Understanding Acute Pancreatitis
Acute pancreatitis is a serious condition characterised by the sudden inflammation of the pancreas, a crucial organ that plays a vital role in digestion. Symptoms typically manifest as intense abdominal pain, nausea, vomiting, and fever, often leading to hospitalisation. While the occurrence of this condition remains rare, the MHRA has recorded a concerning uptick in reports through its Yellow Card scheme, which tracks adverse drug reactions.
As of now, there have been 1,143 reported instances of acute and chronic pancreatitis among users of semaglutide and tirzepatide, with a tragic count of 17 fatalities. The vast majority of these reports—973—came in 2025 alone, predominantly linked to tirzepatide (807 cases) compared to semaglutide (166 cases). Additional reports include 146 cases from patients using liraglutide and 61 from those taking dulaglutide.
Recommendations for Patients and Healthcare Professionals
Dr Alison Cave, the chief safety officer at the MHRA, has emphasised the organisation’s commitment to patient safety, asserting that the benefits of GLP-1 medications outweigh the risks for the majority of users. Nevertheless, she urged patients and healthcare providers to remain vigilant and to recognise the symptoms associated with pancreatitis.
“If you, or someone you care for, is taking GLP-1s and you notice symptoms such as severe, persistent stomach pain that may radiate to the back, along with nausea and vomiting, we strongly recommend consulting a healthcare professional and reporting any concerns through our Yellow Card scheme,” Dr Cave stated.
In addition, the MHRA has initiated the Yellow Card Biobank study in collaboration with Genomics England. This research aims to investigate whether genetic factors may influence an individual’s susceptibility to pancreatitis, ultimately helping to tailor safer medication prescriptions.
Industry Response and Ongoing Safety Measures
In light of the MHRA’s announcement, a spokesperson for Novo Nordisk, the manufacturer of Wegovy and Ozempic, reiterated the company’s commitment to patient safety. They advised that these medications should only be used for their approved purposes and under the supervision of qualified healthcare professionals who can provide guidance on potential side effects.
Eli Lilly, the producer of Mounjaro, has been approached for further commentary on the situation.
Why it Matters
The recent warnings from health authorities underscore the importance of ongoing monitoring and communication regarding the safety of widely used medications. As the prevalence of obesity continues to rise, understanding the risks associated with weight-loss drugs is essential for patient safety. By raising awareness of potential side effects, healthcare providers can ensure that patients make informed decisions about their treatment options, ultimately contributing to better health outcomes in the long run.
